Somaxon Pharmaceuticals
Growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription
About Somaxon Pharmaceuticals
Somaxon Pharmaceuticals, Inc. operated as a specialty pharmaceutical company from its inception in August 2003 until its acquisition in 2013. The San Diego-based firm was co-founded by David F. Hale, a serial entrepreneur with extensive experience in founding and developing life sciences companies, and Kenneth M. Cohen, who served as the initial President and CEO. Cohen brought significant pharmaceutical industry experience, including managing the historic launch of Prozac during his tenure at Eli Lilly and Company. Hale, who served as Chairman, had a long history of leadership roles at companies like Hybritech and CancerVax.
The company's business model centered on in-licensing, developing, and commercializing proprietary branded pharmaceutical products targeting the central nervous system (CNS) therapeutic area. Somaxon's strategy involved identifying late-stage product candidates that could be repurposed or reformulated for new uses, thereby aiming for a more streamlined development and regulatory path. The company went public with an IPO on December 15, 2005, raising capital to advance its clinical programs.
Somaxon's lead product was Silenor® (doxepin), a prescription drug for the treatment of insomnia characterized by difficulty with sleep maintenance. The product's distinction lay in its use of a very low dose of doxepin, a tricyclic antidepressant that has been available for decades at much higher doses. This low-dose formulation was designed to selectively target histamine receptors to improve sleep without causing the significant next-day residual effects or abuse potential associated with many other sleep aids. The U.S. Food and Drug Administration (FDA) granted approval for Silenor in March 2010, a major milestone for the company following two previous rejections. Revenue was generated through the commercial sales of Silenor to patients with insomnia.
In December 2012, Pernix Therapeutics Holdings, Inc. announced a definitive agreement to acquire Somaxon in a stock-for-stock transaction valued at approximately $25 million. The acquisition was completed in March 2013, marking the end of Somaxon's operations as an independent entity and the integration of Silenor into Pernix's product portfolio.
Source: Dealroom company dataNews
Open roles
Somaxon Pharmaceuticals in the Solana Beach ecosystem
The Somaxon Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Domain Associates
Scale Venture Partners- WPWindamere Venture Partners
CDIB BioScience Ventures- MPMontreux Equity Partners
Series B and later1 investor entered at this stage
MPM BioImpact
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Somaxon Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Somaxon Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

